Prescription Pattern of Glucose-lowering Drugs in Patients with Controlled Type 2 Diabetes Mellitus Attending Dhaka Medical College Hospital.

The increasing number of patients with diabetes mellitus imposes an enormous burden on both the healthcare authorities and healthcare providers. The study's objective was to explore the prescription pattern of glucose-lowering drugs for patients with controlled type 2 Diabetes Mellitus (T2DM) attending a tertiary hospital in Bangladesh. This cross-sectional study was conducted at the Endocrinology Outpatient Department of Dhaka Medical College Hospital, Dhaka, Bangladesh, for one year (February 2017 to January 2018). A total of 120 patients aged >12 years with T2DM were included in the study. Prescription analysis and demographic data were collected and recorded in the pre-designed case record form. Among the 120 prescriptions, the number of drugs prescribed per encounter ranged from 1 to 4. Oral drugs were prescribed most frequently (n=88, 73.3%), followed by different preparations of insulin; both (oral and insulin) were prescribed in 13.3% (n=16) of cases. Single drugs were used in 76.7% (n=92) of patients, whereas combined fixed-dose formulation and both types of formulation (single drug and combined fixed dose) were used in 17.5% and 5.8%, respectively. Of all, Metformin was the single most common (67.5%; n=81) drug prescribed by the physicians, followed by Gliclazide (n=19, 15.84%), Glibenclamide (n=14, 11.67%), and short-acting insulin (n=14, 11.67%). Besides, the overall drug use pattern in prescription showed most frequently used drugs were Metformin + Sulphonylureas (21.7%), Metformin (19.2%), Metformin + DPP-4 inhibitors (14.2%), Insulins (13.3%), DPP-4 inhibitors (9.2%) and Metformin + Insulin (9.2%) with a small share of other drugs. Moreover, short-acting insulin was used more commonly (n=14, 11.67%) than other formulations of insulin: long-acting insulin (n=13, 10.83%), premixed insulin (n=12, 10%), intermediate-acting insulin (n=5, 4.16%) and ultra short-acting insulin (n=2, 1.67%).

Clinico-epidemiological Characteristics of Asymptomatic and Symptomatic COVID-19-Positive Patients in Bangladesh.

As of August 15, 2020, Bangladesh lost 3591 lives since the first Coronavirus disease 2019 (COVID-19) case announced on March 8. The objective of the study was to report the clinical manifestation of both symptomatic and asymptomatic COVID-19-positive patients. An online-based cross-sectional survey was conducted for initial recruitment of participants with subsequent telephone interview by the three trained physicians in 237 adults with confirmed COVID-19 infection in Bangladesh. The study period was 27 April to 26th May 2020. Consent was ensured before commencing the interview. Collected data were entered in a pre-designed case record form and subsequently analyzed by SPSS 20.0. The mean±SD age at presentation was 41.59±13.73 years and most of the cases were male (73.0%). A total of 90.29% of patients reside in urban areas. Among the positive cases, 13.1% (n=31) were asymptomatic. Asymptomatic cases were significantly more common in households with 2 to 4 members (p=0.008). Both symptomatic and asymptomatic patients shared similar ages of presentation (p=0.23), gender differences (p=0.30) and co-morbidities (p=0.11). Only 5.3% of patients received ICU care during their treatment. The most frequent presentation was fever (88.3%), followed by cough (69.9%), chest pain (34.5%), body ache (31.1%), and sore throat (30.1%). Thirty-nine percent (n=92) of the patients had co-morbidities, with diabetes and hypertension being the most frequently observed. There has been an upsurge in COVID-19 cases in Bangladesh. Patients were mostly middle-aged and male. Typical presentations were fever and cough. Maintenance of social distancing and increased testing are required to meet the current public health challenge.

Prevalence and Risk Factors of Secondary Hyperparathyroidism among CKD Patients and Correlation with Different Laboratory Parameters.

Hyperthyroidism is one of the major complications in CKD patients who results in a number of metabolic disorders and contributes to morbidity and mortality. The objective of the study was to investigate the prevalence and risk factors for secondary hyperparathyroidism among CKD patients as well as its correlation with different laboratory parameters. This was a cross-sectional study conducted among the admitted CKD patients of Sylhet MAG Osmani Medical College Hospital, Sylhet, Bangladesh from January 2019 to December 2019. Following recruitment, clinical parameters were extracted from the patients' medical records. Afterward, blood sample blood was collected to measure the biochemical parameters and serum parathyroid hormone levels. A binary logistic regression model was used to assess the factors associated with hyperparathyroidism. The mean±SD serum PTH in all CKD patients was 215.04±168.15 pg/ml. The overall prevalence of secondary hyperparathyroidism among CKD patients was 75.0% (32.0% in stage 3, 88.0% in stage 4 and 93.0% in stage 5 CKD). Serum PTH levels had a significant positive correlation with serum creatinine and serum phosphate levels and a significant negative correlation with serum albumin and serum calcium levels. However, only female sex was revealed as a significant risk factor in the adjusted regression model (aOR 0.26, 95% CI 0.07-0.98 for male sex compared to female sex). As the prevalence of secondary hyperparathyroidism increases in advanced stages of CKD, early detection and management of CKD are crucial to prevent metabolic disorders that could trigger the development of this complication.